Fig. 4
From: PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study
Changes of PD-L1 protein expression. PD-L1 (ab PD-L1 SP124) expression is observed in the same patient but monitored at different time lapse: (a) RMS2 (at first progression, pretreated with radiotherapy and chemotherapy) is completely lacking PD-L1 expression (TC0,IC0); (b) while RMS13 (at second progression and post several lines of treatments) display a consistent pattern of staining (TC0, IC3) by the immune cells present outside and inside the tumor burden